Cantor Fitzgerald Cuts Humana (NYSE:HUM) Price Target to $201.00

Humana (NYSE:HUM) had its target price trimmed by Cantor Fitzgerald from $290.00 to $201.00 in a report published on Thursday morning, Marketbeat reports. The brokerage currently has a neutral rating on the insurance provider’s stock.

Several other research analysts also recently commented on the company. Sanford C. Bernstein reiterated an “outperform” rating and set a $344.00 target price on shares of Humana in a research note on Tuesday, January 6th. KeyCorp reaffirmed a “sector weight” rating on shares of Humana in a research report on Friday, December 12th. Barclays reissued an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Finally, Robert W. Baird decreased their price target on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Seven research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $238.29.

Humana Stock Performance

Shares of HUM opened at $183.92 on Thursday. The company has a market cap of $22.12 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 2.04 and a beta of 0.44. The firm has a 50-day moving average of $244.65 and a 200-day moving average of $261.05. Humana has a one year low of $169.61 and a one year high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The business had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. During the same period last year, the business posted ($2.16) EPS. Humana’s revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities analysts forecast that Humana will post 16.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Sound View Wealth Advisors Group LLC boosted its stake in shares of Humana by 3.5% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after buying an additional 36 shares during the period. Unison Advisors LLC raised its holdings in Humana by 0.4% in the 3rd quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock valued at $2,646,000 after acquiring an additional 37 shares in the last quarter. CoreCap Advisors LLC lifted its position in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Insigneo Advisory Services LLC grew its holdings in shares of Humana by 3.0% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after purchasing an additional 43 shares in the last quarter. Finally, Columbus Macro LLC increased its position in shares of Humana by 5.5% in the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock worth $210,000 after purchasing an additional 43 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.